Assorted news from last week: Provocative article written by pediatric cancer advocates, including several CAC2 members — innovation can be crippled by commercialization — meaning next better treatments are completely at the mercy of companies who now have income from drug sales from approved drugs and may not agree to provide the drug for further testing in combinations, etc. To encourage drug companies (sponsors) to develop effective treatments for childhood cancer, authorities in the United States (US) and Europe have made new rules for drug development, and this team from Pfizer has some recommendations to help sponsors maximize their chances of […]

Assorted news from last week: Save the Date:  CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies reported their work in the most recent edition  of European Journal of Cancer.  The Forum was sponsored by ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. CAC2 Member Oncoheroes Biosciences Inc., a biotech focused on advancing new therapies for childhood cancer, has out-licensed worldwide the adult rights to Notable Labs, Inc. (“Notable”), a clinical-stage predictive precision medicine company.  Under the terms of this […]

Assorted news from last week: Save the Date:  CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The Children’s Brain Tumor Network (CBTN) has collected tumor samples from patients at 26 member institutions all over the world. Through funding from the Childhood Cancer Data Initiative of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).  CBTN will procure molecular characterization for thousands of these brain tumor samples providing an unprecedented level of insight into devastating cancers and paving the way for future therapeutic interventions. Compassionate use case of DAY101 demonstrates a complete response in a pediatric patient with a recurrent spindle cell sarcoma harboring a BRAF gene fusion. Despite the relative rarity […]